Description du sujet
The occurrence of multidrug-resistance (MDR) bacteria is on the rise worldwide. In the case of pneumonia, last resort antibiotics can still be active but an increasing number of reports show resistance. In this context, new solutions for the treatment of pulmonary infections due to MDR bacteria, would lies in new antibiotics formulations.
This project aims at developing formulations based on a “pro-drug” approach of an antibiotic combined to efficient biocompatible nanocarriers using fluorescent reporters and florescent imaging.
A 3 years PhD position funded by the ANR-PAANIC is available at the University of Strasbourg. This collaborative and multidisciplinary project involved a co- supervision of the PhD project between two research teams in line with a 10-years collaborative experience in the development of fluorescent nanocarriers for applications in bioimaging and biomedicine (the “Nanochemistry and Bioimaging” laboratory, CNRS in Illkirch, and the “Regenerative NanoMedecine”, Inserm within the CRBS in Strasbourg).
The candidate will have to develop and synthesize pro-antibiotic and fluorescent reporters that will be efficiently encapsulated in lipid nanocarriers. This thesis will mainly include multi-step organic synthesis but also spectral characterizations (absorption and fluorescence spectroscopy), formulation and characterization of nanoparticles, and encapsulation studies.
The candidate will be trained in fluorescence imaging techniques to characterize the diffusion of the nanocarriers in various biomimetic media. The skills aimed to be acquired by the candidate within this PhD research project will be pluridisciplinary, in the field of chemistry and nanomedicine.
References : Wang et al. Nanomaterials 2021, 11 (3), 826. https://doi.org/10.3390/nano11030826 Belcastro et al. Nanomedicine Nanotechnol. Biol. Med. 2021, 34, 102379. https://doi.org/10.1016/j.nano.2021.102379 Rehman et al. Soft Matter 2020. https://doi.org/10.1039/D0SM01952F Klymchenko et al. Adv. Healthc. Mater., https://doi.org/10.1002/adhm.202001289; Bou et al. Soft Matter 2020, 16 (17), 4173–4181. https://doi.org/10.1039/D0SM00077A Bou et al. J. Mater. Chem. B 2020. https://doi.org/10.1039/D0TB00783H Wang et al. ACS Appl. Mater. Interfaces 2019, 11 (14), 13079–13090. https://doi.org/10.1021/acsami.8b22297
Nature du financement : Financement public/privé
Précisions sur le financement : ANR
Présentation établissement et labo d’accueil
UMR CNRS 7021, LABORATOIRE DE BIOIMAGERIE ET PATHOLOGIES, UNIVERSITÉ DE STRASBOURG
The main objective of our laboratory is through a multidisciplinary approach (combining physics, chemistry, pharmacology, biochemistry, molecular and cell biology) at the different scales of life (from the molecule to the animal) to investigate molecular and cellular mechanisms involved in viral and bacterial infections, and tumor signaling, and to propose new therapeutic clues.
Our laboratory is composed of about 100 persons, including 50 scientists (researchers, University teachers, clinicians, engineers, technicians) and administrative agents, and 50 postdocs, PhD and Master students.
Intitulé du doctorat : Doctorat de Chimie
Pays d’obtention du doctorat : France
Etablissement délivrant le doctorat : Université de Strasbourg
Ecole doctorale : ED222 – Ecole doctorale des sciences chimiques
Profil du candidat : the candidate must have good knowledge and a strong motivation for multi-step organic synthesis.
The candidate will benefit from a very favorable environment on site including: automated “flash chromatography” purification system, HPLC / mass analysis platform, 400/500 MHz NMR, preparative HPLC, spectrophotometer and fluorimeter, confocal microscopes.
Candidater sur le site de l’Association Bernard Gregory.